Beruflich Dokumente
Kultur Dokumente
Available at www.sciencedirect.com
ScienceDirect
A R T I C L E I N F O A B S T R A C T
Article history: Background: There is a paucity of published data on the effect of TB chemotherapy on nitric
Received 6 February 2014 oxide (NO) synthesis and metabolism in newly diagnosed and relapsed patients with or
Accepted 20 February 2014 without multi-drug resistant tuberculosis (MDRTB).
Available online xxxx Methods: The pattern of NO response in 140 patients with pulmonary TB, including 74 with
MDR-TB and 66 without MDR-TB has been studied and compared to the NO status of 30
Keywords: healthy donors. Patients comprised those with newly diagnosed TB and recurrent or
Pulmonary tuberculosis relapsed TB. The NO status was assessed by measuring inducible NO synthase (iNOS)
MDR-TB and nitrites and nitrates levels. This was measured prior to treatment initiation and two
MTB months after the prescribed chemotherapy.
Nitric oxide Results: Increased levels of NO indices were found in patients with tuberculosis when com-
NO pared to healthy controls. After two months of chemotherapy a significant decrease in NO
Inducible NO synthase indicators was observed in the patients with TB, particularly in those without MDR-TB and
newly diagnosed TB. The decline in NO activity was less prominent in patients with recur-
rent TB and MDR-TB, which suggests lower level of immunologic and reparative processes
in such patients.
Conclusion: Changes in serum levels of nitrites and nitrates as well as iNOS activity in neu-
trophils may serve as diagnostic criteria to differentiate various clinical forms of TB and
help as prognostic tool to predict treatment outcome.
Ó 2014 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights
reserved.
* Corresponding author. Address: Department of Phtysiatry and Pulmonology, Kharkiv National Medical University, 4 Lenin Avenue,
Kharkiv 61022, Ukraine. Tel.: +380 977723777.
E-mail address: dddimad@yandex.ua (D.O. Butov).
Abbreviations: MDR-TB, multi-drug resistant TB; MTB, Mycobacterium tuberculosis; NO, nitric oxide; iNOS, inducible NO synthase; NDTB,
newly diagnosed TB; RTB, recurrent TB
http://dx.doi.org/10.1016/j.ijmyco.2014.02.003
2212-5531/Ó 2014 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights reserved.
Please cite this article in press as: DO Butov et al. Changes in nitric oxide synthase and nitrite and nitrate serum levels in patients with or without
MDR-TB undergoing the intensive phase of anti-tuberculosis therapy. Int. J. Mycobacteriol. (2014), http://dx.doi.org/10.1016/j.ijmyco.2014.02.003
2 International Journal of Mycobacteriology x x x ( 2 0 1 4 ) x x x –x x x
Please cite this article in press as: DO Butov et al. Changes in nitric oxide synthase and nitrite and nitrate serum levels in patients with or without
MDR-TB undergoing the intensive phase of anti-tuberculosis therapy. Int. J. Mycobacteriol. (2014), http://dx.doi.org/10.1016/j.ijmyco.2014.02.003
International Journal of Mycobacteriology x x x ( 2 0 1 4 ) x x x –x x x 3
Study population
N=140
Table 1 – Nitric oxide synthase (iNOS) activity and levels of nitrates and nitrites in patients with pulmonary
tuberculosis prior to and after 2-month TB chemotherapy as compared with healthy controls (Mean ± SD).
Groups and Nitrates Nitrites iNOS
subgroups (lmol/L) (lmol/L) (pmole/min/mgB)
Before After 2 months Before After 2 months Before After 2 months
treatment of treatment treatment of treatment treatment of treatment
1 MDR-TB (N = 74) 62.89 ± 1.42a,b 46.65 ± 1.04a,b,d 5.626 ± 0.15a,b 4.21 ± 0.13a,b,d 231.6 ± 6.65a,b 114.9 ± 3.2a,b,d
1A recurrent MDR-TB 59.29 ± 1.79b,e,h 49.38 ± 1.3b,d,e,h 5.027 ± 0.17b,e,h 4.42 ± 0.14b,d,f,h 208.4 ± 8.26b,e,h 125.3 ± 4.5b,d,e,h
(N = 41)
1B new Dx MDR-TB 67.36 ± 2.03b,g,k 43.26 ± 1.5b,d,g,k 6.371 ± 0.19b,g,l 3.93 ± 0.13c,d,g,k 260.4 ± 8.56b,g,k 102 ± 3.53b,d,g,k
(N = 33)
2 TB (N = 66) 72.02 ± 1.43b 35.65 ± 1.06c,d 6.747 ± 0.17b 3.67 ± 0.09c,d 286.3 ± 5.92b 91.4 ± 2.53b,d
b,i
2A recurrent TB (N = 15) 66.26 ± 1.89 40.53 ± 1.83c,d,i 5.686 ± 0.2b,i
4.04 ± 0.19c,d,i 260.9 ± 14.12 b,i
106.7 ± 5.2b,d,i
2B new Dx TB (N = 51) 73.72 ± 1.71b,j 34.22 ± 1.19b,d,j 7.059 ± 0.19b,j 3.56 ± 0.1c,d,j 293.7 ± 6.13b,j 86.7 ± 2.59c,d,j
3 Controls (N = 30) 37.98 ± 1.3 3.83 ± 0.093 81.03 ± 2.36
a Discrepancy is significant (p < 0.001) when Groups 1 and 2 are compared.
b Discrepancy is significant (p < 0.05) when compared with Group 3.
c Discrepancy is not significant (p > 0.05) when compared with Group 3.
d Discrepancy is significant (p < 0.001) when compared before treatment and after two months levels among Subgroups.
e Discrepancy is significant (p < 0.05) when Subgroup 1A and 2A are compared.
f Discrepancy is not significant (p > 0.05) between Subgroups 1A and 2A.
g Discrepancy is significant (p < 0.01) between Subgroups 1B and 2B.
h Discrepancy is significant (p < 0.05) between Subgroups 1A and 1B.
i Discrepancy is significant (p < 0.05) between Subgroups 2A and 2B.
j Discrepancy is significant (p < 0.001) between Subgroups 1A and 2B.
k Discrepancy is not significant (p > 0.05) between Subgroups 2A and 1B.
l Discrepancy is significant (p < 0.05) between Subgroups 2A and 1B.
patients with NDPTB. When RPTB patients with MDR are com- of indices of RPTB with MDR and those of NDPTB without
pared to patients with relapsed TB without MDR, the more MDR reveals a significant difference between these subgroups
reliable indicators of NO were observed in TB patients without (p < 0.05). Moreover, when RPTB without MDR is compared
MDR than in those with MDR before treatment (p < 0.05). After with NDPTB with MDR, the differences were insignificant
two months of chemotherapy the indices were higher in TB (p > 0.05) both prior to treatment as well as after the two
patients with MDR than in TB patients without MDR. The months, which suggests that the clinical course is more se-
same outcome was observed in patients with NDPTB with vere in patients with relapsed TB.
or without MDR. The levels of nitrites after the two months When NO indicators in healthy controls were compared
in the RPTB patients with MDR and without MDR were not with treated TB patients, practically the same nitrite levels
affected in a significant manner (p > 0.05). The comparison were observed (p > 0.05) in the following subgroups: 1B, 2B
Please cite this article in press as: DO Butov et al. Changes in nitric oxide synthase and nitrite and nitrate serum levels in patients with or without
MDR-TB undergoing the intensive phase of anti-tuberculosis therapy. Int. J. Mycobacteriol. (2014), http://dx.doi.org/10.1016/j.ijmyco.2014.02.003
4 International Journal of Mycobacteriology x x x ( 2 0 1 4 ) x x x –x x x
and 2A. The nitrate levels were the same in Groups 2 and 2A who contributed their effort made this study possible. Our
and iNOS activity in Subgroup 2B. This suggests the gratitude is expressed to many experts in TB and immunology
normalization of the NO metabolism in the above Groups fields who kindly shared with us their opinions and critiques
and Subgroups. In the remaining groups of patients the differ- prior to and after this study was completed.
ences in NO indices were significant (p < 0.05) as compared
with healthy controls.
R E F E R E N C E S
Conclusions
[1] M.S. Koo, S. Subbian, G. Kaplan, Strain specific transcriptional
In patients with pulmonary TB, significantly higher levels of
response in Mycobacterium tuberculosis infected macrophages,
NO activity were observed as compared with the levels in Cell Commun. Signal. 10 (2012) 2–6.
healthy individuals. In patients with recurrent TB and MDR- [2] H.I. Boshoff, C.E. Barry, Tuberculosis – metabolism and
TB, significantly lower levels of NO indicators were observed respiration in the absence of growth, Nat. Rev. Microbiol. 1
by comparison with patients with newly diagnosed pulmon- (2005) 70–80.
ary tuberculosis. [3] Z.T. Isakova, Z.K. Goncharova, E.U. Iusupova, O.A. Pak,
A.F. Tumashova, M.D. Kozhomkulov, et al, Statistically
After two months on chemotherapy, a significant decrease
mapping modeling of the spread of rifampicin-resistant
in iNOS activity and NO metabolites was observed in patients
M. tuberculosis strains in different regions of the
with pulmonary TB, but the decrease of NO indicators was Kyrghyz Republic, Probl. Tuberk. Bolezn. Legk. 7 (2007)
manifested mostly in the NDPTB patients and patients with- 33–36.
out MDR as opposed to patients with recurrent TB and [4] WHO, Guidelines for Surveillance of Drug Resistance in
MDR-TB, which suggests lower levels of immunologic and Tuberculosis, WHO, Geneva, 2009. p. 83.
reparative processes in such patients. [5] WHO, Anti-Tuberculosis Drug Resistance in The World:
Report No 4, Geneva, 2008, p. 151.
Therefore, the levels of nitrites and nitrates as well as iNOS
[6] Plan to Combat Extensively Drug-Resistant Tuberculosis,
activity may serve as additional diagnostic criteria to differen- Recommendations of the Federal Tuberculosis Task Force,
tiate MDR-TB from non-resistant TB in patients with relapsed 2009, p. 43.
and newly diagnosed TB. Easily assessed NO-related markers [7] C. Dye, Doomsday postponed? Preventing and reversing
can also serve as predictors of treatment outcome since pa- epidemics of drug-resistant tuberculosis, Microbiology 7
tients with drug-susceptible strains had lower NO output (2009) 81–87.
approaching levels found in controls. Further studies are war- [8] O.B. Nechaeva, E.I. Skachkova, Causes and factors of
development of drug resistance in pulmonary tuberculosis,
ranted to elucidate the relationship between NO and resis-
Probl. Tuberk. Bolezn. Legk. 9 (2003) 6–8.
tance of mycobacteria to TB drugs. [9] C.Y. Chiang, R. Centis, G.B. Migliori, Drug-resistant
tuberculosis: past, present, future, Respirology 3 (2010) 413–
Author contributions 432.
[10] S.L. Plieva, P.P. Seltsovskiy, Features of early and late
Conceived and designed the trial: D.O. Butov, M.M. recurrence of pulmonary tuberculosis, Probl. Tuberk. Bolezn.
Legk. 6 (2011) 23–27.
Kuzhko. Carried out the trial: D.O. Butov, I.M. Kalmykova,
[11] V.M. Petrenko, S.O. Cherenko, I.B. Byalyk, M.V. Pohrebna, L.M.
I.M. Kuznetsova, T.S. Butova, O.O. Grinishina, O.A. Mak- Tsygankova, N.A. Lytvynenko, et al, Evolution and
simenko. Analyzed the data: D.O. Butov, M.M. Kuzhko. Wrote effectiveness of antimycobacterial therapy in patients with
the paper: D.O. Butov, M.M. Kuzhko, T.S. Butova. pulmonary tuberculosis relapse, Ukrainian Pulmonol. J. 3
(2009) 14–19.
[12] E.I. Skachkova, O.B. Nechaeva, E.V. Aref’eva, N.V. Iasinetskaia,
Funding
Monitoring of tuberculosis recurrences: their causes and
precipitating factors, Probl. Tuberk. Bolezn. Legk. 8 (2008) 16–
The study was supported by a grant from the Ukrainian Min- 19.
istry of Education. The funder had no role in study design, [13] R.I. Abdullaev, G.O. Kaminskaia, O.G. Komissarova, E.V.
data collection and analysis, decision to publish, or prepara- Glotova, Serum nitric oxide level in the assessment of
tion of the manuscript. systemic inflammation in patients with drug-resistant
pulmonary tuberculosis, Probl. Tuberk. Bolezn. Legk. 5 (2009)
40–43.
Competing interests [14] J. Idh, M. Mekonnen, E. Abate, W. Wedajo, J. Werngren, K.
Ängeby, et al, Resistance to first-line anti-TB drugs is
The authors have declared that no competing interests exist. associated with reduced nitric oxide susceptibility in
Mycobacterium tuberculosis, PLoS One 6 (2012) 39891.
Conflict of interest [15] S.C. Van Beek, N.V. Nhung, D.N. Sy, P.J. Sterk, E.W. Tiemersma,
F.G. Cobelens, Measurement of exhaled nitric oxide as a
potential screening tool for pulmonary tuberculosis, Int. J.
We have no conflict of interest to declare.
Tuberc. Lung Dis. 2 (2011) 185–192.
[16] P.T. Liu, R.L. Modlin, Human macrophage host defense
Acknowledgements against Mycobacterium tuberculosis, Curr. Opin. Immunol. 20
(2008) 371–376.
We thank all volunteers who participated in this study. The [17] A.F. Vanin, Nitric oxide in biomedical research, Bull. RAMS 4
(2000) 3–5.
wholehearted support of clinicians, nurses and lab personnel
Please cite this article in press as: DO Butov et al. Changes in nitric oxide synthase and nitrite and nitrate serum levels in patients with or without
MDR-TB undergoing the intensive phase of anti-tuberculosis therapy. Int. J. Mycobacteriol. (2014), http://dx.doi.org/10.1016/j.ijmyco.2014.02.003
International Journal of Mycobacteriology x x x ( 2 0 1 4 ) x x x –x x x 5
[18] L.V. Sakhno, N.A. Khonina, O.V. Norkina, G.V. Mostovaia, S.D. [20] I.I. Topchy, I.K. Kondakov, T.V. Horbach, O.M. Kiriyenko,
Nikonov, A.P. Ogirenko, et al, Involvement of nitric oxide in Methods for determining violations of L-arginine-nitric
the development of tuberculin energy in patients with nitrogen in the treatment of chronic kidney disease:
pulmonary tuberculosis, Probl. Tuberk. 8 (2001) 42–46. methodical instructions, Ministry of Health of Ukraine, Kiev,
[19] V.A. Metelskaya, N.G. Gumanova, Screening method for 2008. p. 23.
determining the level of nitric oxide in blood serum, Clin. [21] S.N. Lapach, A.V. Chubenko, P.N. Babich, Statistical methods
Lab. Serv. 6 (2005) 15–18. in biomedical studies using Excel, Kiev, 2000, p. 320.
Please cite this article in press as: DO Butov et al. Changes in nitric oxide synthase and nitrite and nitrate serum levels in patients with or without
MDR-TB undergoing the intensive phase of anti-tuberculosis therapy. Int. J. Mycobacteriol. (2014), http://dx.doi.org/10.1016/j.ijmyco.2014.02.003